Ephedrine Sulfate

Narcolepsy, Migraine, Catarrh + 13 more

Treatment

20 Active Studies for Ephedrine Sulfate

What is Ephedrine Sulfate

Ephedrine

The Generic name of this drug

Treatment Summary

Pseudoephedrine is a drug related to ephedrine and is extracted from plants that have been used in traditional Eastern medicine for centuries. Pseudoephedrine was first studied in the West in 1889 and its decongestant effect on dogs was discovered in 1927. It works by affecting the sympathetic nervous system, but not as strongly as ephedrine.

Rynatuss

is the brand name

image of different drug pills on a surface

Ephedrine Sulfate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rynatuss

Ephedrine

1960

36

Effectiveness

How Ephedrine Sulfate Affects Patients

Pseudoephedrine helps to clear up congestion by narrowing blood vessels. It works quickly, but the effects may not last long unless it is taken as a special extended-release medication. Patients should be aware that taking pseudoephedrine can lead to stimulation of the central nervous system.

How Ephedrine Sulfate works in the body

Pseudoephedrine acts as a stimulant on your body, working on alpha and beta adrenergic receptors. This causes your blood vessels to narrow, making it useful for reducing congestion. It is also used to treat long-term erections. Pseudoephedrine also affects the way that hormones and neurotransmitters are transported throughout the body, increasing heart rate, blood pressure, and other bodily functions. It also blocks certain proteins from activating, which helps to reduce inflammation.

When to interrupt dosage

The suggested measure of Ephedrine Sulfate is contingent upon the diagnosed disorder, including Upper Respiratory Tract Infection, Airway secretion clearance therapy and Coughing. The quantity of dosage is contingent upon the method of delivery (e.g. Tablet, extended release or Oral) featured in the table beneath.

Condition

Dosage

Administration

Migraine

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Pharyngitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Narcolepsy

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Myasthenia Gravis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Catarrh

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Acute Bronchitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Depression

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Rhinorrhea

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Asthma

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Coughing

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Arthralgia

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Nasal Congestion

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Upper Respiratory Disease

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Hypotension

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Fever

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Hypersensitivity

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Syrup - Oral, Syrup, Solution - Intramuscular; Intravenous; Subcutaneous, Ointment, Ointment - Nasal, Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Injection - Intravenous, Suppository, Suppository - Rectal, Rectal, Liquid - Infiltration; Subcutaneous, Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Bead, Bead - Oral, Intramuscular; Subcutaneous, Liquid - Nasal, Topical, Spray, Spray - Topical

Warnings

Ephedrine Sulfate has five contraindications and should not be used while experiencing any of the conditions outlined in the table below.

Ephedrine Sulfate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ephedrine Sulfate.

Common Ephedrine Sulfate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be increased when used in combination with Ephedrine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when used in combination with Ephedrine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Ephedrine.

Acebutolol

Major

The therapeutic efficacy of Acebutolol can be increased when used in combination with Ephedrine.

Amphetamine/Dextroamphetamine

Major

The therapeutic efficacy of Amphetamine can be increased when used in combination with Ephedrine.

Ephedrine Sulfate Toxicity & Overdose Risk

The toxic dose of pseudoephedrine in rats is 2206mg/kg and 726mg/kg in mice. Symptoms of overdose may include dizziness, headache, nausea, vomiting, increased heart rate, chest pain, difficulty urinating, muscle weakness, anxiety, restlessness, insomnia, mental confusion, abnormal heart rhythms, loss of consciousness, seizures, and difficulty breathing. Treatment for an overdose should include supportive care and removal of the drug from the body.

Ephedrine Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ephedrine Sulfate?

270 active trials are currently investigating the potential of Ephedrine Sulfate to mitigate Allergic Reactions, Migraines, and Eye Ailments.

Condition

Clinical Trials

Trial Phases

Pharyngitis

0 Actively Recruiting

Myasthenia Gravis

19 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Arthralgia

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Fever

2 Actively Recruiting

Phase 4, Not Applicable

Depression

299 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Hypotension

0 Actively Recruiting

Acute Bronchitis

6 Actively Recruiting

Not Applicable, Phase 3, Early Phase 1, Phase 4

Hypersensitivity

1 Actively Recruiting

Phase 4

Coughing

0 Actively Recruiting

Narcolepsy

5 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Asthma

1 Actively Recruiting

Phase 4

Upper Respiratory Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Catarrh

1 Actively Recruiting

Not Applicable

Migraine

16 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Ephedrine Sulfate Reviews: What are patients saying about Ephedrine Sulfate?

4.7

Patient Review

12/12/2008

Ephedrine Sulfate for Bronchitis

4.3

Patient Review

4/9/2009

Ephedrine Sulfate for Bronchitis

I had never tried Bronkaid before, but I decided to give it a shot since I was struggling with my asthmatic bronchitis. I'm really glad I did- within half an hour, I could tell that it was working better than any other over the counter medication I've used for this problem.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ephedrine sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does ephedrine do to a person?

"The ephedrine alkaloids are weak stimulants that can mildly increase heart rate and blood pressure, as well as relaxing bronchial tissue to ease shortness of breath."

Answered by AI

Is ephedrine sulfate a stimulant?

"Ephedrine is a central nervous system (CNS) stimulant that has been used to prevent low blood pressure during anesthesia, as well as for asthma, narcolepsy, and obesity. While it is not the preferred treatment, it is still used for these purposes."

Answered by AI

How do you take ephedrine sulfate?

"Ephedrine sulfate injection must be diluted with normal saline or 5% dextrose in water before administration as an intravenous bolus to achieve the desired concentration."

Answered by AI

What is ephedrine sulfate used for?

"This drug is indicated for the treatment of allergic disorders such as bronchial asthma. It has been used as a pressor agent for a long time, particularly during spinal anesthesia when hypotension is common."

Answered by AI

Clinical Trials for Ephedrine Sulfate

Image of McLean Hospital in Belmont, United States.

D-Cycloserine + TMS for Mental Health

18+
All Sexes
Belmont, MA

This study is testing whether combining a rapid form of transcranial magnetic stimulation (TMS), an oral medication called d-cycloserine (DCS), and therapy can improve brain flexibility and emotional control in adults experiencing moderate-to-severe depression, anxiety, or trauma symptoms. TMS is a non-invasive treatment that uses gentle magnetic pulses to stimulate specific areas of the brain. In this phase of the study, all participants receive active accelerated TMS (delivering multiple brief sessions in a single day) along with DCS, a medication that helps enhance brain learning and plasticity. Participants will be randomly assigned to have TMS directed at one of two brain targets: a region called the precuneus (identified using personalized brain scans) or the dorsolateral prefrontal cortex (a standard area for mood treatment). Afterward, participants are randomly assigned to complete three weeks of either therapist-led talk therapy (a modified Unified Protocol) or self-guided educational videos and readings. The main goals are to determine which brain stimulation target works best and to see whether therapist-led therapy leads to more lasting symptom relief and brain changes compared to self-guided education.

Phase 2
Waitlist Available

McLean Hospital

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Relationship or Family Issues

Any Age
All Sexes
Pine Ridge, SD

Although research documents the concerning rates of mental and behavioral health problems (e.g., substance use/initiation) among Indigenous LGBTQ2S+ youth, there is very little known about how to prevent these deleterious issues that devastate Indigenous communities. The study will include \~40 families (Lakota LGBTQ2S+ youth and caregivers) in Rapid City, SD (20 families (10 FAP; 10 wait-list control) and on the nearby Pine Ridge Indian Reservation (10 FAP; 10 wait-list control). Following the baseline survey, families will be randomly assigned to the treatment or wait-list control. Participants will complete an immediate post-test and 6-month follow-up survey to test the hypotheses that FAP will lead to changes in targets, specifically increases in caregiver accepting behaviors, youth and caregiver connection to Lakota culture, family bonding, and youth future orientation and decreases in caregiver rejecting behaviors, caregiver harsh parenting, and youth internalized homo/bi/transphobia compared to the control condition. The researchers will also examine the hypotheses that there will be reductions in deleterious primary outcomes (depressive symptoms, anxiety symptoms, suicidality) and secondary outcomes (alcohol and drug use/initiation and dating and sexual violence victimization and perpetration) among youth in the treatment conditions compared to the control condition. Additionally, the researchers will assess the acceptability and feasibility of the FAP via program observations, post-session surveys, and exit interviews.

Waitlist Available
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Summit Hyperbarics and Wellness in Boise, United States.

Hyperbaric Oxygen Therapy for Traumatic Brain Injury

18 - 75
All Sexes
Boise, ID

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are: 1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions? 2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment? Approximately 54 participants will: * Complete medical and behavioral health screening. * Complete cognitive tests and questionnaires before and after treatment. * Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions. All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

Phase 2
Recruiting

Summit Hyperbarics and Wellness

Steve Wyman, MD

Image of Attune Neurosciences, Inc. in San Francisco, United States.

Focused Ultrasound for Depression, Anxiety, and OCD

22 - 80
All Sexes
San Francisco, CA

This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.

Waitlist Available
Has No Placebo

Attune Neurosciences, Inc.

Attune Neurosciences Inc

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs in Colorado Springs, United States.

Parenting-STAIR Modular for PTSD and Depression

18+
All Sexes
Colorado Springs, CO

The goal of this clinical trial is to learn if a family-based treatment called Parenting-STAIR-Modular (PSTAIR-M) can help military parents recover from trauma, strengthen emotion regulation skills, and improve parent-child relationships. Participants will be trauma-exposed active-duty Service Members (SM) or their spouses who screen positive for PSTD and/or depression, and one identified child (ages 2-10). The main questions it aims to answer are: 1) Does PSTAIR-M reduce parental PTSD and depression symptoms, lower parenting stress, and improve child behavior compared to treatment-as-usual?; and 2) Is PSTAIR-M feasible and acceptable when delivered to military families stationed overseas? Researchers will compare PSTAIR-M to treatment-as-usual (TAU) to see if PSTAIR-M leads to greater improvements in parental PTSD, depression, parenting stress, emotion regulation, child maltreatment risk, and child behavior than usual care. Participants will: 1) attend 12-16 weekly, 1-hour online treatment sessions with their assigned clinicians, 2) complete three 1-hour online assessments administered by research staff, 3) engage with their child in three 15-30-minute online, observed play sessions, 4) have assessments and observed play sessions audio and video recorded.

Waitlist Available
Has No Placebo

Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs (+3 Sites)

Kathrine S Sullivan, PhD

Image of Medical University of South Carolina in Charleston, United States.

CHW Support for Post-Traumatic Stress Disorder

18+
All Sexes
Charleston, SC

This pilot study will evaluate the feasibility, acceptability, and preliminary effectiveness of the Trauma Resilience and Recovery Program Plus (TRRP+), a Community Health Worker-enhanced intervention designed to improve behavioral health engagement and recovery among adult trauma survivors with unmet social needs. One hundred adult trauma patients admitted to the Medical University of South Carolina (MUSC) Level I Adult Trauma Center who screen positive for risk of posttraumatic stress disorder (PTSD) or depression and report at least one unmet social need will receive TRRP+ services. Participants will complete assessments at baseline, 1 month, and 3 months after enrollment. The study will also examine implementation barriers and facilitators to support future dissemination and scale-up of the intervention.

Waitlist Available
Has No Placebo

Medical University of South Carolina

Theresa Skojec, PhD

Image of Stony Brook University in Stony Brook, United States.

Behavioral Activation for Depression and Autism

12 - 17
All Sexes
Stony Brook, NY

Autism spectrum disorder is characterized by differences in social communication/interaction and the presence of restricted/repetitive behaviors, with significant heterogeneity in terms of autistic features, language ability, and cognitive characteristics. About 2-3% of individuals in the United States are autistic, and most autistic individuals have co-occurring mental health conditions. Autistic people are 3-4 times more likely to experience depression than non-autistic people. Of the emerging depression treatment research with autistic people, none to date has focused on developing and testing a depression treatment for autistic youth with below average cognitive abilities - a group which comprises over 50% of the autistic community. Therefore, this study seeks to evaluate the feasibility (Aim 1), acceptability (Aim 2), and preliminary treatment effects (Aim 3) of an extension of Behavioral Activation for Depression in Autistic Adolescents (BA-A), adapted to meet the needs of cognitively lower functioning autistic youth.

Recruiting
Has No Placebo

Stony Brook University

Michelle Menezes, PhD

Image of Online Therapy Unit in Regina, Canada.

'Things You Do' Program for Depression and Anxiety

18+
All Sexes
Regina, Canada

Research shows that the single lesson 'Things You Do' Intervention is effective in increasing engagement in everyday healthy actions. However, no research has examined whether its effectiveness is enhanced by incorporating personalized feedback on participants' current level of engagement in healthy actions. In this randomized controlled trial, clients will be randomly assigned to either receive or not receive personalized feedback informing them of their level of engagement in healthy actions over the previous week and encouraging them to participate in more healthy activities. The investigators will examine whether this feedback increases engagement in healthy actions and enhances the effectiveness of the 'Things You Do' Intervention as assessed through changes in primary outcomes.

Recruiting
Has No Placebo

Online Therapy Unit

Heather Hadjistavropoulos, PhD

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of University of Chicago in Chicago, United States.

Virtual Group Therapy for Inflammatory Bowel Disease

18+
All Sexes
Chicago, IL

This study is being done to better understand the complex relationship between mental health and Inflammatory Bowel Disease (IBD), with a particular focus on symptoms of depression and anxiety. While depression and anxiety have traditionally been viewed as reactions to the burden of living with IBD, new research suggests that the biological factors involved in IBD may also contribute directly to these mental health challenges. This study aims to evaluate whether a virtual, group-based psychological treatment is both acceptable and feasible for patients with IBD who experience significant depression and/or anxiety. Researchers will also evaluate participants' depression, generalized anxiety, and associated psychosocial factors (poor sleep quality, GI-specific anxiety, fatigue) before, during, and after treatment. Finally, researchers will evaluate disease severity as it relates to mental health status by comparing it to symptoms, biochemical disease and tryptophan metabolites from blood and stool samples. People who agree to join the study will be asked to attend three in-person visits and 10 virtual group psychotherapy sessions over 11 weeks. Participants will be asked to complete questionnaires, give stool and blood samples, and the research team will collect information about participations from medical records.

Waitlist Available
Has No Placebo

University of Chicago

Alyse Bedell, PhD, CST

Image of Ear, Nose, & Throat Surgeons of Western New England in Springfield, United States.

Treatment for Headache

18+
All Sexes
Springfield, MA

The goal of this double-blinded, randomized placebo controlled clinical trial is to to see if using a numbing medicine (lidocaine) on certain areas inside the nose can help with headaches, neck pain, facial pain and pressure, and other symptoms. It also aims to understand the pathophysiology that causes these symptoms. The main questions it aims to answer are: 1. Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to treat migraine headaches immediately and 24 hours? 2. Is applying numbing medication directly to the sphenopalatine ganglion (SPG) area, while watching through the scope to make sure it's in the right place, a workable and effective way to improve patient-reported outcomes? The 2-month study requires: * One virtual visit (on the computer) * One visit to the office for placement of the numbing medicine under direct vision * Daily headache diary entries that take less than two minutes to complete

Phase 2
Waitlist Available

Ear, Nose, & Throat Surgeons of Western New England

Jerry Schreibstein, MD

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials